April 18, 2024

Healthcare Associated Infections (HAI) Surveillance Solutions is the largest segment driving the growth of Infection Surveillance Solutions Market

The global Infection Surveillance Solutions Market is estimated to be valued at US$ 683.8 Mn or Mn in 2023 and is expected to exhibit a CAGR of 14% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Infection surveillance solutions involves software and services that help healthcare organizations to continuously monitor and prevent the occurrence of healthcare-associated infections. It provides patient-level clinical and microbiological data for analysis to control infections.

Market key trends:
One of the key trends in the infection surveillance solutions market is the shift from manual to automated surveillance systems. The manual surveillance process is time-consuming and prone to errors. The automated infection surveillance solutions use electronic health records, microbiology databases and admission-discharge-transfer data to monitor infections continuously with improved accuracy. Several players are focusing on developing artificial intelligence and analytics integrated solutions to provide earlier detection of infections, predict outbreaks and aid in clinical decision making. For instance, Wolters Kluwer provides an AI-driven surveillance and clinical decision support platform called HealthWatch that continuously monitors patient-level data to provide real-time infection insights.

Do not write anything about key players event though data is provided. Do not write conclusion anywhere in the output.
Here is the content in the requested format:

Market key trends:
The infection surveillance solutions market is witnessing high growth due to increasing prevalence of hospital acquired infections. Hospital acquired infections or HAIs are infections that patients acquire while receiving treatment for medical or surgical conditions. One of the key trends in this market is the rising demand for automated and integrated infection surveillance solutions from healthcare facilities to efficiently screen, track, and monitor HAIs. Automated solutions help analyze large amounts of data from electronic medical records and clinical documentation to detect infections early and enable quick clinical intervention.

SWOT Analysis
Strength: Automated surveillance solutions provide accurate, consistent and timely detection of HAIs which improves patient safety and clinical outcomes.
Weakness: High upfront investment and maintenance costs of automated solutions restricts adoption rates.
Opportunity: Growing geriatric population and increasing chronic diseases will continue driving demand for long-term patient care centers, boosting market opportunities.
Threats: Stringent regulatory guidelines and compliance issues pose threats to market players. Lack of skilled professionals for data analytics also threatens market growth.

Key Takeaways
The global infection surveillance solutions market size was valued at US$ 683.8 Mn in 2023. The market is expected to witness high growth, exhibiting a CAGR of 14% over the forecast period of 2023 to 2030, due to increasing incidence of HAIs worldwide.

Regional analysis: North America dominated the market in 2023 and is expected to retain its dominance over the forecast period. This is attributed to increasing focus of government and healthcare facilities on patient safety through infection control initiatives in the region. Asia Pacific is projected to exhibit the fastest growth during the analysis period supported by growing medical tourism, rising chronic disease prevalence, and increasing government investments in healthcare infrastructure development in emerging countries.

Key players operating in the infection surveillance solutions market are Baxter, BD, STERIS, Getinge AB, Medtronic, Koninklijke Philips N.V., Abbott, Medexter Healthcare, Asolva, GOJO Industries, Inc., Wolters Kluwer N.V., VigiLanz Corporation, RLDatix, Roper Technologies Inc., Health Outcomes Worldwide, OpGen, Inc., Urovant Sciences and Premier.